Six Pharma Cos Get Notice for Overpricing (India)
This article was originally published in PharmAsia News
Executive Summary
India's National Pharmaceutical Pricing Authority (NPAA) has begun taking action against drug companies accused of producing overpriced or unapproved medications. Previously 11 pharmaceutical companies had volunteered to cut prices on 886 drugs. NPAA investigations found that six companies were not complying with the reduction on 58 different medications. They also discovered that 39 unapproved versions the 886 drugs had been made available. (Click here for more
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.